EcoDrugPlus

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSDLEG00000008878
Gene Symbol: FRK
3 Cross references
217 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSDLEG00000001819
Gene Symbol: GLA
3 Cross references
197 Possible Orthologues:

Galectin 1

Ensembl ID : ENSDLEG00000009929
Gene Symbol: LGALS1
3 Cross references
327 Possible Orthologues:

Galectin 3

Ensembl ID : ENSDLEG00000007025
Gene Symbol: LGALS3
1 Cross references
218 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSDLEG00000000155
Gene Symbol: GABRA1
3 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSDLEG00000012369
Gene Symbol: GABRA2
3 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSDLEG00000000127
Gene Symbol: GABRA3
3 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSDLEG00000012324
Gene Symbol: GABRA4
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSDLEG00000007067
Gene Symbol: GABRA5
3 Cross references
259 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6

Ensembl ID : ENSDLEG00000000216
Gene Symbol: GABRA6
3 Cross references
266 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta1

Ensembl ID : ENSDLEG00000012313
Gene Symbol: GABRB1
3 Cross references
100 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta2

Ensembl ID : ENSDLEG00000000252
Gene Symbol: GABRB2
3 Cross references
277 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).